Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

Biomolecules. 2018 Dec 10;8(4):169. doi: 10.3390/biom8040169.


Introduction: Pancreatic cancer (PC) is a lethal malignancy. Various diagnostic, predictive, and prognostic biomarkers have been evaluated. This study was conducted to investigate the serum levels of neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) in patients with PC and the relationship between tumor progression and known prognostic parameters.

Materials and methods: Serum samples were obtained on first admission before any treatment. Serum NEDD9 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched healthy controls were included in the analysis.

Results: In a three year period, 32 patients with a pathologically-confirmed diagnosis of PC were enrolled in this study. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men (n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx (chemotherapy) were CTx-responsive. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (p = 0.03). Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, and LDH levels were found to be significant prognostic factors (p = 0.006, p < 0.001, and p < 0.001, respectively). However, serum NEDD9 levels had no significantly effect on progression free survival (PFS) and overall survival (OS) (p = 0.71 and p = 0.58, respectively).

Conclusions: NEDD9 is identified as a secretory biomarker for PC but it has no prognostic role.

Keywords: NEDD9; diagnostic; pancreatic cancer; serum.

MeSH terms

  • Adaptor Proteins, Signal Transducing / blood*
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / blood*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pancreatic Neoplasms / blood*
  • Pancreatic Neoplasms / pathology
  • Phosphoproteins / blood*
  • Prognosis*
  • Progression-Free Survival


  • Adaptor Proteins, Signal Transducing
  • Biomarkers, Tumor
  • NEDD9 protein, human
  • Phosphoproteins